Depolarizing bipolar disorder: both the illness and our views

"Depolarizing bipolar disorder: both the illness and our views." Australian and New Zealand Journal of Psychiatry, 45(11), pp. 909–910

Declaration of interest: MB has received grant or research support from the NIH, Stanley Medical Research Foundation, MBF, National Health and Medical Research Council (NHMRC), beyondblue, Geelong Medical Research Foundation, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma, and Servier; has been a speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay, and Wyeth; and served as a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, and Servier. GSM has received grant or research support from NHMRC, NSW Health, AstraZeneca, Eli Lilly, Organon, Pfizer, Servier, and Wyeth; has been a speaker for AstraZeneca, Eli Lilly, Janssen Cilag, Lundbeck, Pfizer, Ranbaxy, Servier, and Wyeth; and has been a consultant for AstraZeneca, Eli Lilly, Janssen Cilag, Lundbeck, and Servier. The authors alone are responsible for the content and writing of the paper.